Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

Commenting on the patent issuance, Mr. William P. Spencer, President of Imagenetix, said, "The issuance is a significant development relating to our novel technology in the therapeutic treatment of periodontal disease and other inflammatory related conditions. Imagenetix now owns a broader range of intellectual property protection on our novel technology with the issuance of this U.S. patent. Through the guidance of Imagenetix's scientists and consultants, who are experts in achieving drug approval in this field, we continue to move forward with our promising drug therapy for the treatment of periodontitis."

Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. In studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group.